Company intelligence / Profile preview

NOTA Laboratories

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Preclinical

Overview

NOTA Laboratories is developing novel nitric oxide delivery systems intended to harness the antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic properties of nitric oxide. Their pipeline includes several NO enhancement technologies in development for a range of respiratory and infectious diseases. The company has received funding from the US National Institutes of Health through the small business innovation program but has not yet reported clinical trial results.

Therapeutic areas: PulmonologyImmunologyInfectious Diseases
Modalities: DeviceSmall molecule
Industry: Therapeutic Medical Devices

Partnerships

US National Institutes of Health SBIR program funding partner

Beyond the preview

Go deeper on NOTA Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOTA Laboratories.

Explore the full profile